BHVN - Biohaven Ltd.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$16.50
DETAILS
HIGH:
$23.00
LOW:
$10.00
MEDIAN:
$16.50
CONSENSUS:
$16.50
UPSIDE:
6.11%
About Biohaven Ltd. (https://www.biohaven.com)
Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Vladimir Coric | Chairman & Chief Executive Officer | 1971 | $1,397,915 USD |
| Matthew Buten | Chief Financial Officer | 1961 | $858,610 USD |
| Bruce D. Car DACVP | Chief Scientific Officer | 1962 | $801,361 USD |
| Kimberly Gentile | Senior Vice President of Clinical Operations | 1966 | $757,722 USD |
| Clifford Bechtold | President, GM of Biohaven Ireland & Chief Compliance Officer | – | – |
| Deb Young | Senior Director of Regulatory Affairs & Operations | – | – |
| George C. Clark | Vice President & Chief Accounting Officer | 1985 | – |
| Jennifer Porcelli | Vice President of Investor Relations | – | – |
| John McGill | Chief Technology Officer | – | – |
| Warren Volles | General Counsel & Chief Legal Officer | – | – |